loading page

High-dose methotrexate therapy for a child with B-cell precursor acute lymphoblastic leukemia and congenital solitary kidney
  • +3
  • Noboru Hokama,
  • Nobuyuki Hyakuna,
  • Satoru Hamada,
  • Hideo Shiohira,
  • Koichi Nakanishi,
  • Katsunori Nakamura
Noboru Hokama
University of the Ryukyus

Corresponding Author:fukudanagai9@gmail.com

Author Profile
Nobuyuki Hyakuna
Hospital of University of the Ryukyu
Author Profile
Satoru Hamada
Ryukyu Daigaku Igakubu Fuzoku Byoin
Author Profile
Hideo Shiohira
University of the Ryukyus
Author Profile
Koichi Nakanishi
Ryukyu Daigaku Igakubu Fuzoku Byoin
Author Profile
Katsunori Nakamura
University of the Ryukyus
Author Profile

Abstract

High-dose methotrexate (HD-MTX) is a key drug in the treatment of various cancers. Massive fluid infusion is necessary during HD-MTX therapy to ensure proper methotrexate excretion. There are no reports on the safety of HD-MTX therapy in patients with congenital solitary kidney (CSK). A 5-year-old male child with CSK and B-cell precursor acute lymphoblastic leukemia was treated with four cycles of HD-MTX therapy. HD-MTX therapy was safely administered without delayed MTX excretion or renal dysfunction. This case showed that HD-MTX therapy was well tolerated by a pediatric patient with CSK.